The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trialOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the Spleen-strengthening and Liver-draining formula (SLF), a Traditional Chinese Medicine preparation based on the 'One Qi Circulation' theory, as a treatment for non-alcoholic fatty liver disease (NAFLD). Because intestinal flora disturbance is a known feature of NAFLD, the researchers focused on whether SLF works partly by altering the gut microbiome and glucolipid metabolism. The study used a prospective, randomized, controlled clinical design over 12 consecutive weeks to test this mechanism.
Who was studied?
The abstract does not give an exact number of participants, but describes NAFLD patients who were randomly and evenly divided into a control group and an SLF treatment group. A healthy control (HC) group was also included for comparison of intestinal flora. Fecal samples from both NAFLD groups were collected before and after the 12-week treatment period and analyzed alongside samples from the healthy controls.
What were the most important findings?
The abstract text provided is cut off before the results are fully described, so specific findings (such as taxa affected or magnitude of change) cannot be stated. What can be confirmed is that the study compared 16S rRNA gene sequencing profiles of intestinal flora across the SLF group, control group, and healthy controls before and after treatment. The design indicates the researchers intended to link any SLF-associated clinical improvement in NAFLD to detectable shifts in gut microbial composition.
What are the greatest implications of this study?
If SLF reliably shifts intestinal flora alongside clinical improvement, it would support gut microbiome modulation as a mechanism behind a traditional herbal therapy for NAFLD. This kind of trial helps bridge Traditional Chinese Medicine practice with microbiome-based explanations that are testable by modern sequencing methods. It also underscores that lifestyle adjustment alone (the control group) is a comparator whose own microbiome effects need to be accounted for when evaluating add-on therapies like SLF.